TF and cancer: Preclinical studies showed the prothrombotic role of TF+ EVs in various tumor models.[27] [28] [29] [30] Hron et al. and others reported that TF+ EVs are known to be associated with VTEs in patients with cancer.[13] [10] On the contrary, Thaler and colleagues measured the EV-associated TF activity and showed that EV-TF activity was not associated with future VTE but associated with mortality in patients with systemic cancer, suggesting that TF+ EV are simply epiphenomenon of disease progression.[14]